Stay updated with breaking news from Angioedema Workshop. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- STAR-0215 Granted Fast Track Designation by the U.S. FDA ---- New Results from Healthy Subjects Informing STAR-0215 Administration Plan Expected in Q4 2023 ---- ALPHA-STAR on Track with Initial Proof-of-Concept Results in Patients Anticipated Mid-2024 --BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:A...
Enrollment completed in Phase 2 CHAPTER-1 prophylactic study; top-line data anticipated by YE2023Clinical hold lifted on deucrictibant for the on-demand treatment of HAE; initiation of global Phase 3...
– Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Target Enrollment; Data Readout Expected in Q4 – – Company Funded Into 2025 With NDA Planned for H1 2024 –
-- Administration of STAR-0215 to HAE Patients is Underway in the ALPHA-STAR Phase 1b/2 Trial ---- ALPHA-STAR on Track for Initial Proof-of-Concept Results Anticipated Mid-2024 ---- Mechanistic Modeling Data Supports STAR-0215 Administration Once Every Three or Six Months for Robust Suppression of HAE Attacks --BOST...
-- Administration of STAR-0215 to HAE Patients is Underway in the ALPHA-STAR Phase 1b/2 Trial -- -- ALPHA-STAR on Track for Initial Proof-of-Concept Results Anticipated Mid-2024 -- -- Mechanistic... | May 11, 2023